Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramin Farboudmanesch

Gastroenterology Chevy Chase, MD Medical Doctor

NPI 1669433215 CMS profile 347656

5454 Wisconsin Ave, 1045, Chevy Chase, MD 20815

Open in the dashboard

General payments

$6,679

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$28,877 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Ramin Farboudmanesch of Chevy Chase, MD is reported in the CMS Open Payments database as having received $6,679 across 335 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,877 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $927 38
2024 General $442 17
2023 General $923 66
2022 General $1,269 65
2021 General $1,395 74
2020 General $732 35
2019 General $990 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramin Farboudmanesch
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ramin Farboudmanesch were reported at $927. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ramin Farboudmanesch Gastroenterology median Middle half National median
2019 $990 $417 $126–$1,100 $163
2020 $732 $224 $74–$624 $114
2021 $1,395 $352 $106–$1,054 $132
2022 $1,269 $448 $129–$1,270 $149
2023 $923 $533 $150–$1,390 $160
2024 $442 $605 $160–$1,606 $164
2025 $927 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,134 76 payments
  2. AbbVie, Inc. $964 42 payments
  3. QOL Medical, LLC $624 25 payments
  4. Celgene Corporation $482 67 payments
  5. Regeneron Healthcare Solutions, Inc. $447 11 payments
  6. Novo Nordisk Inc $339 13 payments
  7. Allergan Inc. $335 8 payments
  8. Ferring Pharmaceuticals Inc. $313 18 payments
  9. Apollo Endosurgery US Inc $266 2 payments
  10. Pfizer Inc. $263 14 payments
  11. Other $1,511 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,419 314 payments
  2. Education $260 21 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,408 85 payments
  2. ZEPOSIA $572 68 payments
  3. CREON $336 20 payments
  4. Sucraid $289 8 payments
  5. LINZESS $270 16 payments
  6. OverStitch Endoscopic Suturing System $266 2 payments
  7. DUPIXENT $249 6 payments
  8. MAVYRET $248 10 payments
  9. Wegovy $245 7 payments
  10. TRULANCE $244 15 payments
  11. Other $3,974 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

514

Median for Gastroenterology: 569

Drug cost

$40,124

Median for Gastroenterology: $104,976

Branded share of claims

44.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 81 $14,171
Linzess Linaclotide Brand 12 $8,124
Voquezna Vonoprazan Fumarate Brand 12 $7,632
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 101 $5,439
Omeprazole Generic 133 $1,458
Dicyclomine Hcl Generic 35 $1,420
Sucralfate Generic 17 $618
Baclofen Generic 11 $448
Pantoprazole Sodium Generic 29 $265
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 21 $210

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$89,869

Medicare's payments for the services billed

Medicare patients

302

Average age 74

Services billed

703

197 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 41%
Chronic kidney disease 29%
Ischemic heart disease 25%
Cancer 18%
Osteoporosis 16%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $119
$119 12 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $46
  • GENZYME CORPORATION $16
$62 — —
Sucraid
  • QOL Medical, LLC $58
$58 — —
RESMETIROM
  • Madrigal Pharmaceuticals $37
$37 — —
GIMOTI
  • EVOKE PHARMA, INC. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record